Avacta Group plc ( (GB:AVCT) ) just unveiled an update.
Avacta Group PLC has provided a business update for the first quarter of 2025, highlighting significant progress in its strategic objectives. The company is advancing its AVA6000 Phase 1b expansion cohorts, with promising data expected later in 2025, and is preparing for a Phase 1 trial of AVA6103 in early 2026. Avacta’s transformation into a pure-play therapeutics company, focusing on its pre|CISION® platform, extends its cash runway into the first quarter of 2026. The company’s presentations at the AACR Annual Meeting underscore the potential of its innovative drug delivery mechanisms, and the recent appointment of Brian Hahn as CFO strengthens its management team.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage life sciences company focused on developing next-generation peptide drug conjugates (PDC) for cancer therapy. The company utilizes its proprietary pre|CISION® platform, which targets tumor-specific proteases to deliver potent anti-tumor payloads directly to the tumor, minimizing damage to healthy tissues.
YTD Price Performance: -23.10%
Average Trading Volume: 1,740,943
Technical Sentiment Signal: Buy
Current Market Cap: £143.3M
For a thorough assessment of AVCT stock, go to TipRanks’ Stock Analysis page.